Phase 3 N=256 T790M Plasma Testing Methodology Comparison and Clinical Validation
Lung Cancer
Primary: Concordance — 91.3; 66.8; 82.7; 86.1 percentage of aggrement
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=19 Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
Multiple Sclerosis · Infusion Reaction
Primary: Proportion of Participants With Infusion-related Reaction (IRR) on Day 0 — 5; 6 participnats
Phase 2 N=46 Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: 4-Cycle Induction Overall Response Rate (ORR) — 95 percentage of participants
Phase 4 N=72 Safety of Gebauer's Pain Ease and Gebauer's Ethyl Chloride
Spray · Pain · Safety Issues
Primary: Presence of Microbial Growth (1+ CFU) — 2; 1; 1; 1 Number of samples with 1+ CFU — p=0.317
N/A N=5,446 Best Practice Alert for Opioid Prescribing
Opioid Use
Primary: Opioids Prescribed at Discharge — 100; 75 miligram morphine equivalents
N/A N=440 BIOTRONIK Orsiro Pre-Marketing Registration
Coronary Artery Disease
Primary: In-stent Late Lumen Loss at 9 Months as Assessed by the Core Laboratory QCA Analysis — 0.05; 0.07 mm
Phase 2 N=45 Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Urinary Toxicity Assessed by CTCAE v4.0 — 33 Participants
Phase 2 N=27 A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
Non-small Cell Lung Cancer Metastatic · Targetable Oncogenes (EGFR, ALK, ROS1)
Primary: 1-year Frequency of Distant Failures (DF) After Stereotactic Body Radiation Therapy (SBRT) — 19 percentage of participants
Phase 2 N=22 Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Kawasaki Disease
Primary: Number of Participants With Adverse Events — 2; 3; 13 participants
N/A N=147 Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)
Ethylene Glycol Poisoning, Methanol Poisoning
Primary: Number of Participants Reporting One or More Adverse Events (AEs) — 22 Participants
Phase 1 N=124 A Study of TAK-510 in Healthy Adults
Healthy Participants
Primary: Parts 1 and 2: Number of Participants Who Met the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose — 0; 0; 0; 0 Participants
Phase 3 N=60 A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Attention Deficit Hyperactivity Disorder
Primary: Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score — -7.6; -2.1 score on a scale — p==.0106
N/A N=89 (MIST1)-Part 1: Assessment & Feasibility of Post-Symptoms Evaluation
Patient Safety · Manipulation, Spinal
Primary: Number of Patient Encounters That Report a New or Worsening Symptom — 8 Participants
N/A N=9 Combined Effects of Early Behavioral Intervention and Propranolol on ASD
Autism
Primary: Change in General Social Outcome Measure (GSOM) — 48.3; 20.0 score on a scale
Phase 2 N=498 Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
Drug and/or Toxin-induced Diarrhea
Primary: Proportion of Patients Experiencing a Maximum Grade ≥ 2 Diarrhea During the First Cycle of Chemotherapy in the Target Population — 2.5; 5.0; 5.8; 9.8 percentage of…